James Wolf Ups Stake In Enzo, May Seek Board Seat

0
James Wolf Ups Stake In Enzo, May Seek Board Seat
albertyurolaits / Depositphotos

Fintel reports that James Wolf has filed a 13D/A form with the SEC disclosing ownership of 4,942,400 shares of Enzo Biochem Inc (NYSE:ENZ). This represents 10.14% of the company.

In is previous filing dated November 23, 2022 Wolf reported 4,168,500 shares and 8.56% of the company, an increase in shares of 18.57% and an increase in total ownership of 1.58% (calculated as current – previous percent ownership.

Wolf said in the filing he may nominate himself for election as a director of the Company at the next annual meeting of shareholders if he is not nominated or approved by the Board of Directors.

Gates Capital Management Reduces Risk After Rare Down Year [Exclusive]

Gates Capital Management's ECF Value Funds have a fantastic track record. The funds (full-name Excess Cash Flow Value Funds), which invest in an event-driven equity and credit strategy, have produced a 12.6% annualised return over the past 26 years. The funds added 7.7% overall in the second half of 2022, outperforming the 3.4% return for Read More

Get Our Activist Investing Case Study!

Get the entire 10-part series on our in-depth study on activist investing in PDF. Save it to your desktop, read it on your tablet, or print it out to read anywhere! Sign up below!

Q4 2022 hedge fund letters, conferences and more

 


Find A Qualified Financial Advisor

Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

If you're ready to be matched with local advisors that can help you achieve your financial goals, get started now.


Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards.

A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Enzo Biochem

What Are Large Shareholders Doing?

Harbert Fund Advisors, Inc. holds 5,175,913 shares representing 10.62% ownership of the company. No change in the last quarter.

 

Renaissance Technologies Llc holds 2,909,664 shares representing 5.97% ownership of the company. In it's prior filing, the firm reported owning 3,016,164 shares, representing a decrease of 3.66%. The firm increased its portfolio allocation in ENZ by 24.21% over the last quarter.

Roumell Asset Management, LLC holds 2,390,211 shares representing 4.91% ownership of the company. No change in the last quarter.

VIEX Capital Advisors, LLC holds 1,334,479 shares representing 2.74% ownership of the company. In it's prior filing, the firm reported owning 1,536,857 shares, representing a decrease of 15.17%. The firm increased its portfolio allocation in ENZ by 14.45% over the last quarter.

Fuller & Thaler Asset Management, Inc. holds 971,010 shares representing 1.99% ownership of the company. In it's prior filing, the firm reported owning 957,485 shares, representing an increase of 1.39%. The firm increased its portfolio allocation in ENZ by 14.23% over the last quarter.

Fund Sentiment

There are 91 funds or institutions reporting positions in Enzo Biochem, Inc.. This is a decrease of 12 owner(s) or 11.65%.

Average portfolio weight of all funds dedicated to Enzo Biochem, Inc. is 0.3169%, an increase of 20.3050%. Total shares owned by institutions decreased in the last three months by 3.34% to 23,764,544 shares.

Article by Fintel

No posts to display